Gallbladder Cancer in the 21st Century

Table 7

Targeted therapy alone or in combination with chemotherapy in gallbladder and biliary tract cancer.

Targeted agent	Disease site	Number; GBC/total	Line of therapy	Response rate	Comments
Single agent targeting VGF
Sorafenib [145]	BTC	12/31	First	6%
Sunitinib [146]	BTC	NA/56	Second	9%
Single agent targeting HER2
Lapatinib [147]	HCC or BTC	17 BTC/57	First & second	0% in BTC
Lapatinib [148]	HCC or BTC	NA/9	Any	0%	Trial was stopped early due to futility
Other single agents
Bortezomib [149]	BTC	6/20	First, second, third	5%	Trial was stopped early due to futility
Selumetinib [150]	BTC	7/28	Second	10%
Doublet of targeted agents
Bevacizumab + erlotinib [151]	BTC	10/53	First	17%
Bevacizumab + erlotinib [152]	Upper GI cancer	16 BTC/102	Second or later	6%
Targeted agents with chemotherapy
GEMOX ± cetuximab [153]	BTC	NA/50	First	23%	Response rate in control group: 29%
GEMOX + cetuximab [154]	BTC	NA/30	First	63%	9 patients underwent resection after response
GEMOX ± cetuximab [155]	BTC	50/122	First	27.3%	Response rate in control group: 15%
GEMOX + bevacizumab [156]	BTC	NA/35	First & second	40%
Gem + triapine [157]	BTC	18/33	First	9%
5FU/LV + imatinib [158]	BTC	19/41	First	8%
GEMOX + erlotinib [159]	BTC	82/268	First	30%	16% in chemotherapy arm alone. No difference in OS

BTC, biliary tract cancer; GEMOX, gemcitabine and oxaliplatin; HCC, hepatocellular cancer; NA, not applicable; OS, overall survival. Modified from [143].